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OBJECTIVE—Regulation of pancreatic -cell mass is essential
to preserve sufﬁcient insulin levels for the maintenance of
glucose homeostasis. Previously, we reported that DNA double-
strand breaks (DSBs) resulting from nonhomologous end-joining
(NHEJ) deﬁciency induce apoptosis and, when combined with
p53 deﬁciency, progressed rapidly into lymphomagenesis in
mice. Combination of NHEJ deﬁciency with a hypomorphic
mutation, p53R172P, leads to the abrogation of apoptosis, up-
regulation of p21, and senescence in precursor lymphocytes. This
was sufﬁcient to prevent tumorigenesis. However, these mutant
mice succumb to severe diabetes and die at an early age. The aim
of this study was to determine the pathogenesis of diabetes in
these mutant mice.
RESEARCH DESIGN AND METHODS—We analyzed the mor-
phology of the pancreatic islets and the function, proliferation
rate, and senescence of -cells. We also proﬁled DNA damage
and p53 and p21 expression in the pancreas.
RESULTS—NHEJ-p53R172P mutant mice succumb to diabetes
at 3–5 months of age. These mice show a progressive decrease in
pancreatic islet mass that is independent of apoptosis and innate
immunity. We observed an accumulation of DNA damage, ac-
companied with increased levels of p53 and p21, a signiﬁcant
decrease in -cell proliferation, and cellular senescence in the
mutant pancreatic islets.
CONCLUSIONS—Combined DSBs with an absence of p53-
dependent apoptosis activate p53-dependent senescence, which
leads to a diminished -cell self-replication, massive depletion of
the pancreatic islets, and severe diabetes. This is a model that
connects impaired DNA repair and accumulative DNA damage, a
common phenotype in aging individuals, to the onset of diabetes.
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lassic nonhomologous end-joining (NHEJ) is
one of the two major pathways for the repair of
DNA double-strand breaks (DSBs) (1). The fac-
tors involved in this conserved pathway are the
DNA-dependent kinase complex (DNA-PKcs) and Ku het-
erodimer, the DNA ligase complex (DNA ligase IV, XRCC4,
Cernunnos/XLF), and a DNA repair factor Artemis (2).
DNA ligase IV and XRCC4 are absolutely required for the
classic NHEJ pathway; deﬁciencies of either render the
cell hypersensitive to DNA-damaging agents, such as ion-
izing radiation, and premature senescence (3).
Mice deﬁcient for NHEJ factors other than Cernunnos/
XLF (4) develop severe combined immunodeﬁciency due
to their failure to join DNA breaks generated during early
lymphoid development in a DNA rearrangement process
termed V(D)J recombination (5). NHEJ deﬁciency results
in the accumulation of unrepaired DNA breaks and p53-
dependent apoptosis in developing lymphoid cells. Some
NHEJ-deﬁcient mice also exhibit defective neuronal devel-
opment, and an accumulation of DNA damage in the
central nervous system that leads to p53-dependent apo-
ptosis, in severe cases such as ligase IV (Lig4)
/ or
XRCC4
/, results in embryonic lethality (6–8).
The embryonic lethality is rescued by p53 deﬁciency
(6,9). Lig4
/ or XRCC4
/ in the p53
/ background can
survive after birth, but succumb to aggressive pro-B lym-
phomas at an early age (10). All these lymphomas carry
chromosomal translocations between the immunoglobulin
and the proto-oncogene c-MYC loci and a complicon
structure that leads to ampliﬁcation of the MYC genes.
Interestingly, a hypomorphic mutant p53, p53
R172P (re-
ferred to as p53
p/p), which is defective in apoptosis but not
in cell cycle arrest (11), not only rescues embryonic
lethality but also entirely eliminates lymphomagenesis in
the Lig4
/ (12). Analyses of Lig4
/p53
p/p mice revealed
extensive senescence in developing lymphocytes with
increased levels of p53 and p21. This indicates that V(D)J
recombination-mediated DSBs, which are unrepaired due
to a lack of end-joining, activate the hypomorphic p53,
thereby transactivating p21 and ultimately driving these
cells into senescence. This p53-p21–driven senescence has
proven effective for suppressing genomic instability and
tumorigenesis in Lig4
/p53
p/p mice.
Despite its potent tumor suppressor activity, cellular
senescence has been described as a mechanism to prevent
cell proliferation as well as resistance to apoptosis. These
properties may cause aging-related diseases (13). Al-
though DNA damage–induced senescence successfully
prevents lymphomagenesis, all Lig4
/p53
p/p mice have an
aging appearance and die before they reach 6 months of
age. We hypothesize that DNA damage–induced senes-
cence may lead to a decrease in cellular proliferation and
organ regeneration or renewal capability. As a result, the
maintenance of homeostasis is compromised. Indeed,
analysis of these mice revealed a gradual depletion of
pancreatic islets and progressive diabetes.
Diabetes arises because of defects in pancreatic -cells,
affecting either cell proliferation and growth or insulin
production, which are crucial for the maintenance of
glucose homeostasis. -Cell replication and islet mass are
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growth factors, and hormone levels in response to various
challenges and physiological demands (14,15). Regulation
of -cell mass includes constant cell proliferation through-
out life, although at different rates over time; continual
cellular turnover is governed by the renewal and loss of
-cells by mechanisms such as apoptosis (16). Disruption
of this balance leads to rapid changes in -cell mass and
pathological conditions such as diabetes. Because in adult
mice -cell self-replication is the main mechanism to
regenerate and maintain the -cell mass (17–20), DNA
damage and its cellular response may disrupt cell prolif-
eration thus leading to an imbalance of -cell mass main-
tenance. Several reports have revealed that senescence
induced by telomeric shortening or other means has been
linked to limiting -cell proliferation and diabetes (21,22).
DNA damage has been considered an extrinsic factor
contributing to cellular senescence, but its impact on
pancreatic -cells has not been addressed. In this report,
we describe the ﬁrst animal model that progressively
develops diabetes with a depletion of pancreatic -cell
mass due to accumulated DNA damage and a p53-depen-
dent response that drives cells into senescence. Our model
indicates that age-related DNA damage accumulation in
the pancreatic -cells, and its associated senescence, may
be one cause of diabetes.
RESEARCH DESIGN AND METHODS
Animals. Mutant mice (mixed C57BL/6 and 129SV) maintenance has been
previously described (12). The protocols were approved by the Institutional
Animal Care and Use Committee at The University of Texas M.D. Anderson
Cancer Center.
Measurement of blood glucose and insulin levels. For the glucose
tolerance test, mice were fasted for 16 h and injected intraperitoneally with
glucose at 1.0 g/kg body wt. For the insulin tolerance test, mice were fasted for
6 h and injected intraperitoneally with insulin at 0.75 units/kg (Sigma).
Glucose levels were measured using a glucose analyzer (Bayer Contour).
Blood insulin levels were measured by enzyme-linked immunosorbent assay
(ELISA).
Pancreatic histology, immunohistochemistry, and immunoﬂuores-
cence. Pancreata were ﬁxed in Shandon Cryomatrix (Thermo Scientiﬁc) and
placed at 20°C or Bouin solution (Ricca Chemical Company) overnight,
dehydrated through ethanol, and embedded in parafﬁn for histological analy-
sis. Sections (6 m) were incubated with antibodies against insulin, glucagon
(Cell Signaling), F480 (eBioscience), Cd11b, Nk1.1 (BD), p53 and p21 (Santa
Cruz), or H2AX (Abcam). For immunohistochemistry, horseradish peroxida-
se–conjugated secondary antibodies were applied per the manufacturer’s
recommendations. A 3,3-diaminodbenzidine (DAB)-chromogen substrate
mixture was applied or combined with 3-amino-9-ethyl carbazole (AEC) for
double immunohistochemical detection. Slides were subjected to hematoxy-
lin-eosin (H-E) staining and examined by light microscopy (Olympus BX41).
For immunoﬂuorescence, secondary antibodies were applied according to the
manufacturers’ recommendations. Slides were analyzed by ﬂuorescent
microscopy.
Analysis of pancreatic morphology. Pancreata sections were prepared as
described; insulin was detected by immunohistochemistry and counterstained
with H-E. Each section was subjected to morphometric analysis using ImageJ
(National Institutes of Health [NIH], Bethesda, MD). The area of the pancreas
and the area of each islet in the tissue were measured. Raw data were
statistically analyzed.
TUNEL assay. Terminal deoxynucleotidyl transferase–mediated dUTP nick-
end labeling (TUNEL) assay kit (Promega) was used to detect apoptosis with
DNase-1–treated sections as positive controls (12).
Pancreatic -cell proliferation. Bromodeoxyuridine (BrdU) was injected
intraperitoneally at 100 mg/kg. After 4 h, pancreata were sectioned. Slides
were incubated with anti-BrdU (Serotec) and anti-insulin antibodies and
analyzed.
Cell senescence. Senescence-associated -galactosidase (-gal) activity was
detected by a staining kit (Cell Signaling). Blocks were sectioned (6 m), and
insulin was detected by immunohistochemical staining. Slides were counter-
stained with Nuclear Fast Red (Vector Labs).
Statistical analysis. Results are presented as the means  SEM. Differences
were determined using a two-tailed, unpaired Student t test with CI of 95%. A
P value 0.05 was denoted as statistically signiﬁcant.
RESULTS
Lig4
/p53
p/p mutant mice exhibit glucose intoler-
ance and impaired insulin production. We previously
showed that Lig4
/p53
p/p mice do not develop lympho-
mas or any other type of tumors, but die within 6 months
of age (12). These mice appeared emaciated, lethargic, and
dehydrated prior to death and presented severe hypergly-
cemia. We monitored nonfasting Lig4
/p53
p/p mice at
different ages and found a progressive increase of blood
glucose levels that was signiﬁcantly different from the
age-matched wild-type mice (Fig. 1A). Signiﬁcant hyper-
glycemia was recorded as early as 2 months of age,
suggesting a postnatal development of diabetes in the
Lig4
/p53
p/p mice.
To determine the time of diabetes onset, we performed
a standard glucose tolerance test in 1- and 3-month-old
mutant mice with wild-type mice as controls. The glucose
tolerance test at 1 month of age did not exhibit a signiﬁ-
cant difference between the two groups (Fig. 1B).
However, 3-month-old Lig4
/p53
p/p mice showed hyper-
glycemia at point zero, and after the glucose injection the
levels increased and remained high during the assay.
These results indicate a progressive impaired glucose
tolerance and diabetes in the mutant mice. We next
determined the blood insulin levels by ELISA in these
mice. Although blood insulin levels were not signiﬁcantly
different at 1 month of age, insulin levels in the 3-month-
old mutant mice were signiﬁcantly lower and were irre-
sponsive to the glucose injection, suggesting insulin
insufﬁciency in these mice (Fig. 1C). Insulin tolerance test
performed on 1-month-old mutant and wild-type mice
revealed no difference between the two genotypes, indi-
cating a normal insulin sensitivity in these mutant mice
prior to diabetes onset (Fig. 1D). Collectively, these results
indicate a progressive insufﬁcient production of insulin
that results in impaired glucose tolerance in the mutant
mice.
Progressive depletion of pancreatic -cells in
Lig4
/p53
p/p mice. Insulin insufﬁciency is a common
characteristic in both types of diabetes. Type 1 diabetes
results from the combined effects of genetic, environmental,
and immunological factors that destroy pancreatic -cells
(23). Type 2 diabetes results from a progressive islet dysfunc-
tion leading to defective -cell secretion and insulin resis-
tance (24,25). In both cases -cell mass decreases, and
residual functional -cells still exist but are insufﬁcient in
number to maintain glucose tolerance. To determine whether
the hyperglycemia observed in the Lig4
/p53
p/p mice was
the result of a progressive decrease in -cell mass, we
examined the morphological changes in the pancreatic islets
by H-E and immunohistochemical staining for insulin. As
shown in Fig. 1E, mutant mice have a relatively normal size
of pancreatic islets compared with the wild-type at 1 week of
age. However, as mutant mice aged, the size of the pancreatic
islets gradually declined. As shown in Fig. 1F, a signiﬁcant
decrease in islet size was observed in the mutant mice as
early as 1 month of age. An almost complete depletion of the
pancreatic islets was observed in the 5-month-old mutant
mice. Immunohistochemical staining for glucagon, indicative
of -cells that signal the liver to break down glycogen to
produce glucose upon hypoglycemia, did not reveal any
abnormalities in these mutant mice. A full panel of islet
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are available in the online appendix at http://diabetes.
diabetesjournals.org/cgi/content/full/db09-0792/DC1.
To obtain a quantitative measurement and assess the
differences of -cell mass in Lig4
/p53
p/p and wild-type
mice, we determined the ratio of islet area to total
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FIG. 1. Lig4
/p53
p/p mice succumb to progressive diabetes and reduction of pancreatic islets. A: Blood glucose concentrations from nonfasting
animals at indicated ages. Glucose levels were signiﬁcantly higher in mutant mice starting at 2 months of age. Each data point was an average
of at least three animals. B: Blood glucose concentrations measured from a glucose tolerance test in wild-type and Lig4
/p53
p/p mice at 1 and
3 months. Three mice from each genotype were tested. C: Blood insulin concentrations were measured by ELISA. D: Standard insulin tolerance
test for insulin sensitivity in 1-month-old wild-type and Lig4
/p53
p/p mice. E: Islet morphometric quantiﬁcation of Lig4
/p53
p/p and wild-type
mice. Multiple sections were analyzed for each pancreas, and three to four mice per group were analyzed; data represent the means  SEM. F:
Representative pancreatic sections from Lig4
/p53
p/p and wild-type mice stained by immunohistochemistry for insulin. *P < 0.0001 versus wild
type. Mon, month; Wk, week; WT, wild type. (A high-quality color digital representation of this ﬁgure is available in the online issue.)
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age (P  0.2452; Fig. 1E). In general, older mutant mice
observed a major reduction in pancreatic islet area. A 46%
reduction in islet area was observed in the mutant mice at
1 month (P  0.0001), although there was no difference in
the ratio of pancreas to body weight between mutant and
wild-type mice (supplementary Fig. 3). By 5 months of age,
a 73% decrease was observed in the mutant mice (P 
0.0001). These results clearly indicate a severe reduction
of the pancreatic islet mass in the mutant mice, correlating
with progressive onset of diabetic phenotype.
Depletion of the pancreatic islets is not due to
apoptosis or innate immunity. Many diabetic models
with resulting -cell loss are due to an increase in islet-
speciﬁc apoptosis (26,27). Although the p53
R172P mutation
prevents the induction of apoptosis, programmed cell
death may occur independently of p53 expression (28). To
test whether apoptosis is the cause of pancreatic islet
depletion observed in mutant mice, we performed a
TUNEL assay in pancreatic sections. No apoptosis was
observed in 1-month-old mutant pancreatic sections,
whereas only a very low level of apoptosis was observed in
wild type at this age (supplementary Fig. 4) compared with
an NHEJ-deﬁcient thymus section. Similar results were
obtained with mice at different ages (results not shown).
These data suggest that pancreatic islet depletion ob-
served in the Lig4
/p53
p/p mice is not due to DNA
damage–induced apoptosis.
Type 1 diabetes is caused by activated immune cells
speciﬁcally attacking pancreatic islets that leads to -cell
depletion. This is unlikely to happen in the Lig4
/p53
p/p
mice as they are deﬁcient in lymphocytes due to an
incomplete V(D)J recombination. Instead, we examined
whether the innate branch of immunity has any involve-
ment in -cell depletion. Pancreatic sections from mice of
different ages were stained for CD11b surface markers,
which identify inﬁltrated granulocytes, monocytes, den-
dritic cells, and natural killer cells. Although many cells
were CD11b positive in the control spleen section, very
few cells were stained positive for CD11b in both mutant
and wild-type pancreatic sections, with undistinguishable
differences. We also stained for the presence of inﬁltrated
macrophages and mast cells using the F4-80 antibody and
toluidine blue, respectively. Similar to CD11b staining,
macrophage and toluidine blue–positive cells were rarely
detected in pancreatic sections from both wild-type and
mutant mice (supplementary Fig. 5). Collectively, these
results suggest that it is unlikely that innate immune cells
are responsible for the destruction of the pancreatic islets
in the mutant mice.
Accumulated DNA damage in the pancreas of
Lig4
/p53
p/p mutant mice. Due to the high energy
consumption, pancreatic -cells are particularly suscepti-
ble to DNA damage caused by intrinsic metabolic agents
such as reactive oxygen species (29). Because these cells
are able to self-replicate, it is absolutely vital to have an
efﬁcient DNA damage repair machinery to maintain the
integrity of the genome. Therefore, we hypothesized that
the NHEJ pathway may be very active in pancreatic
-cells. To test this hypothesis, we performed a Western
blot on puriﬁed wild-type pancreatic islets. Our results
showed that indeed DNA ligase IV level is high in pancre-
atic islets (supplementary Fig. 6) and is comparable with
the level detected in the testis, a tissue that is known to
have high DNA ligase expression (30).
The high expression level of DNA ligase IV in pancreatic
islets led us to predict that DNA damage should accumulate
in pancreatic islets of Lig4
/p53
p/p mice (3). To determine
whether H2AX foci, indicative of DNA damage, accumulate
in the mutant pancreas, we stained 2- and 4-month-old
pancreatic sections from the Lig4
/p53
p/p and wild-type
mice. H2AX foci were detected throughout the 2-month-old
mutant but not in the wild-type sections. By 4 months,
intense H2AX foci were observed in most mutant sections,
indicating DNA damage was accumulative; this is in clear
contrast to the absence of foci observed in the wild-type
pancreas. Furthermore, sections that were costained for
insulin and H2AX showed high DNA damage in the pancre-
atic islets (Fig. 2A). These results indicate that in the absence
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FIG. 2. Accumulation of DNA damage and elevated p53 and p21 in Lig4
/p53
p/p mice. A: Pancreatic sections were stained for insulin by
immunoﬂuorescence (red), H2AX foci (green), and DAPI (blue) in 2- and 4-month-old Lig4
/p53
p/p and wild-type mice. H2AX foci visualized
in Lig4
/p53
p/p are more intense in 4- than in 2-month-old mutant mice. No H2AX foci were visible in wild-type mice. Double immunohisto-
chemical staining of pancreatic sections from 2- or 3-month-old Lig4
/p53
p/p and wild-type mice for (B) p21 and (C) p53 (black) in combination
with insulin (red-brown). Magniﬁcation 40. Mon, month; WT, wild type. (A high-quality color digital representation of this ﬁgure is available
in the online issue.)
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lative DNA damage.
Elevation of p53 and p21 results in cellular senes-
cence in the pancreas of Lig4
/p53
p/p mutant mice.
NHEJ deﬁciency results in the failed end-joining of Rag-
mediated DNA breaks in the thymus and bone marrow of
Lig4
/p53
p/p mice, leading to activation of p53 and p21, as
previously reported (12). We asked whether accumulated
DNA damage in the pancreas also stimulates p53 and p21
expression in Lig4
/p53
p/p mice. Because DNA damage
occurs randomly in the pancreas, as opposed to the
programmed DNA damage in developing lymphocytes, we
did not detect a similar expression of p53 and p21.
However, p53 and p21 were detected in some pancreatic
islets of mutant mice (Fig. 2B and C). Virtually no p53 or
p21 was detected in age-matched wild-type pancreatic
sections. These results indicate that accumulated DNA
damage induces a p53-p21–dependent response in the
pancreas of the Lig4
/p53
p/p mice.
Decreased proliferation of -cells in Lig4
/p53
p/p
mice. Slow proliferation is a major source for the mainte-
nance of pancreatic -cell mass and glucose homeostasis
(17,18). We hypothesized that exposure to chronic DNA
damage could lead to suppression in -cell proliferation
that eventually results in the loss of -cell mass in
Lig4
/p53
p/p mice. To test this hypothesis, we compared
the -cell proliferation rates by BrdU incorporation. Pro-
liferating pancreatic cells, positive for incorporated BrdU,
were identiﬁed by immunohistochemical and immunoﬂu-
orescent staining. No differences in proliferation rates
were observed at 1 week of age, but a discrete nonsignif-
icant 28% decrease (P  0.285) in -cell proliferation was
observed in pancreas of 1-month-old Lig4
/p53
p/p mice
(Fig. 3A). A signiﬁcant decrease of 60% (P  0.0001) and
62% (P  0.05) in -cell proliferation was observed in 2-
and 3-month-old mutant mice, respectively, as opposed to
their wild-type counterparts. Representative sections are
shown in Fig. 3B. These results strongly correlate with the
appearance of the diabetic phenotype, suggesting a direct
relationship between the decline in -cell proliferation,
due to the accumulation of DNA damage, and the onset of
diabetes.
Activated p53-p21 promotes cellular senescence as a
mechanism to suppress genomic instability and tumor-
igenesis in the thymus and bone marrow of the mutant
mice. We asked whether the random accumulation of
DNA damage, which induces p53-p21 activation, could
also render pancreatic cells to undergo cellular senes-
cence. Pancreata from mutant and age-matched wild-
type mice were stained for acidic -gal activity, which
indicates cellular senescence. The results demonstrated
progressive -gal accumulation in all three mutant mice
at 1, 2, and 3 months of age. Importantly, positive -gal
staining is colocalized with insulin-positive islets, indi-
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FIG. 3. Decreased -cell proliferation and increased cellular senescence in Lig4
/p53
p/p mice. A: Percentage of BrdU incorporation in -cells of
the total -cells was measured in each age group of Lig4
/p53
p/p mice and plotted in comparison with age-matched wild-type mice. n > 2 mice
per time point. Data are the means  SEM. *P < 0.05 versus wild type. B: Representative islet proliferation of pancreatic sections incubated with
anti-BrdU antibody (green) and costained with anti-insulin antibody (red). Arrows indicate BrdU-positive cells. Magniﬁcation 40. C:
Immunohistochemical staining for insulin (brown) and -gal (blue) staining of pancreatic sections from age-matched Lig4
/p53
p/p and wild-type
mice. Counterstaining with nuclear fast red. Magniﬁcation 100. Mon, month; Wk, week; WT, wild type. (A high-quality color digital
representation of this ﬁgure is available in the online issue.)
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senescence (Fig. 3C). No senescent cells were detected
in age-matched wild-type pancreatic sections. Remark-
ably, whereas DNA damage induction of p53-p21 and
senescence is beneﬁcial in the developing lymphocytes
to suppress genomic instability and prevent tumorigen-
esis, senescence in the pancreatic -cells actually halts
cell proliferation, leading to a depletion of islets and
insulin insufﬁciency, resulting in diabetes.
DISCUSSION
Our study presents a unique animal model in which
accumulating DNA damage, due to a deﬁciency of end-
joining, leads to upregulation of p53-p21 and senescence in
pancreatic -cells. This p53 activity diminishes the self-
replication capability of -cells, resulting in a severe loss
of the pancreatic islet number and diabetes. Our animal
model further emphasizes the importance of cell replica-
tion in already differentiated -cells for the homeostasis of
islet mass and glucose metabolism. This is also a unique
animal model that implicates the accumulation of DNA
damage due to impaired DNA repair, a typical phenotype
of aging, leading to the onset of diabetes. Therefore, this is
signiﬁcant for our understanding of diabetogenesis and
offers potential insight into future therapies.
Diabetes occurs when -cells fail to produce enough
insulin for metabolic demands due to their dysfunction or
just simply failure to maintain the islet cell mass (14,31). In
adult mice, this -cell mass is maintained by self-
replication rather than differentiation from stem cells or
neogenesis (17,18). Therefore, factors mediating -cell
proliferation directly impact their maintenance; mice de-
ﬁcient for these factors have defective -cell replication
leading to a reduction in cell number and the development
of diabetes. Such examples are CDK4-deﬁcient (32,33) or
Cyclin D2–deﬁcient (18,34) mice; both models have a
progressive reduction of -cell number and gross onset of
diabetes with features of hyperglycemia and glucose intol-
erance. Conversely, overexpression of Cyclin D1 (35) or
CDK4 (32) in the pancreas leads to hyperplasia of pancre-
atic islet cells, indicating the importance of these key
molecules and highlighting the critical role of cell prolif-
eration in the maintenance of -cells. Our results are in line
with these models. Furthermore, it appears that neonatal and
adulthood -cell maintenance is dictated by different mech-
anisms. While both Cyclin D2– and CDK4-deﬁcient newborn
mice have relatively normal pancreatic islets, a progressive
reduction in -cell mass occurs as the animals age. The
Lig4
/p53
p/p mice have a very similar pattern of progressive
development of diabetes, strongly suggesting that the reduc-
tion in -cell proliferation leads to the decrease in -cell
numbers and results in severe diabetes.
Cyclin-dependent kinase inhibitors, the Kip and Cip
family of proteins along with the INK4/ARF family, play
essential roles in regulating cell proliferation (15) and
therefore directly impact -cell maintenance. Overexpres-
sion of p16
INK4a (36) or p27
kip1 (37) leads to a decrease in
-cell proliferation rate and reduction in -cell mass.
Conversely, p16
INK4a (36), p18
INK4c,o rp 2 7
kip1 (38) deﬁ-
ciency results in pancreatic islet hyperplasia. These results
indicate that these CDK inhibitors are important regula-
tors of cell proliferation in the pancreatic -cells. Although
cell cycle inhibitor and p53 downstream target p21 is
expressed in pancreatic -cells (39,40), islets grow and
function normally in p21 deﬁciency, suggesting that other
cell cycle inhibitors may function to compensate for the
absence of p21. Interestingly, p21 is upregulated in murine
pancreatic islets when overexpressing potent mitogens
such as hepatocyte growth factor or placental lactogene,
depicting the importance of p21 in the inhibition of growth
factor–driven proliferation in murine islets. Therefore,
p21, although not vital for normal -cell proliferation and
function, plays an important role when -cells are under
stress. Our previous study demonstrated that in response
to genetically programmed DNA damage, p53 and its
downstream target p21 are critical for driving cells into
cell cycle arrest and senescence in developing lympho-
cytes (12). In this study, the same DNA damage–respon-
sive pathway is activated, driving -cells into senescence.
Such a strong inhibitory mechanism of cell proliferation
plays a pivotal role blocking -cell proliferation.
The maintenance of homeostasis is dependent on a ﬁne
regulation of cellular proliferation potential, and the tumor
suppressor p53 plays a key role in this regulation. Our
NHEJ-deﬁcient mice are unique models to demonstrate this
concept. NHEJ deﬁciency in the absence of p53 leads to
rapid tumorigenesis in the developing lymphoid cells, due to
the presence of unrepaired physiological DNA breaks in
proliferating cells that lead to chromosomal translocation
and oncogene activation (10,41). The hypomorphic p53
R172P
successfully rescued this tumorigenic process because the
residual p53 activity is able to respond to physiological or
other DNA damage and blocks cell proliferation to prevent
genomic instability. But this potent tumor suppression mech-
anism comes with a price. We propose that persistent DNA
damage due to NHEJ deﬁciency leads to p53-dependent
senescence, a program that requires cells to undergo dra-
matic chromatin remodeling. This leads to the shutdown of
DNA replication, preventing the cells from entering the cell
cycle. Senescence also leads to the silencing of many genes
related to cell metabolism and cell growth. This accumulative
event speeds the aging process and is deleterious to those
organs that require constant regeneration and renewal, such
as in pancreatic islets. We propose that Lig4
/p53
p/p mice
develop severe diabetes due to the incapability of -cell
proliferation and the failure to maintain the critical -cell
mass. Accumulative DNA damage and p53-induced senes-
cence may be the main contributors to the inhibition of -cell
proliferation. However, we cannot rule out that other effects
accompanying senescence, such as the silencing of critical
genes required for sensing growth signals, lead to -cell
irresponsiveness. Further investigation is required to address
this matter. Additionally, due to the severe reduction of -cell
number in 3-month-old and older mice there must be a
mechanism to remove senescent -cells by means other than
apoptosis. In this context, autophagy may play a role to clear
out senescent cells and to recycle proteins/nutrients; further
investigation is currently ongoing. Similar results have been
recently reported on mice deﬁcient for the pituitary tumor
transforming gene (PTTG), which encodes an inhibitor for
separase, which regulates chromatid separation during mei-
osis. Interestingly, deﬁciency of PTTG leads to a progressive
upregulation of p21 that drives pancreatic -cells into senes-
cence that eventually results in insulinopenic diabetes (42).
It has been hypothesized that both accumulative DNA
damage and cellular response to DNA damage are potential
contributing factors for aging (43). Consistent with this
hypothesis, our studies on this unique animal model showed
accumulation of DNA damage, and its p53-dependent re-
sponses have a profound impact on the proliferation rate and
functions of pancreatic -cells. Deﬁciency in DNA repair
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damage occurs frequently in pancreatic -cells (29), and
NHEJ activity is important to repair the damage and maintain
the integrity of the genome. It is the mutation in DNA damage
response that gradually leads to the halting of the cellular
proliferation. Both accumulation of DNA damage and gene
mutations may require a long process to develop and could
be major causative factors of aging. Interestingly, our study
highlights the importance of the cell cycle inhibitor p21 in
regulating -cell proliferation in response to genomic stress.
DNA damage–induced cellular senescence may be a potent
tumor suppressing mechanism, yet it also diminishes regen-
eration/renewal capacity of certain organs and leads to
aging-related diseases, such as diabetes with depletion of
pancreatic islets.
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